Aro Bio Therapeutics

Aro is expanding Nucleic Acids Chemistry team to design and synthesize novel Centyrin-oligonucleotide conjugate therapeutics. In this role, you will report to Aro’s Chief Technology Officer and become a key member of the chemistry team.

Responsibilities

  • Provide leadership and guidance to a growing nucleic acid chemistry team working on discovery programs to identify lead molecules in rare/genetic diseases/immunology
  • Design and execute synthesis strategies for oligonucleotides (siRNA, ASO etc.) to support discovery and pre-clinical programs
  • Function as subject matter expert, collaborate with internal CMC team and external CDMOs to support oligonucleotide development and manufacturing activities
  • Design and synthesize novel phosphoramidites to explore oligonucleotide SAR studies to improve biological, biophysical properties and to expand IP
  • Responsible for managing timelines, deliverables and executing against corporate goals
  • Represent oligonucleotide chemistry team in our external collaborations
  • Carryout hands-on laboratory work
  • Collaborate with internal/external bioinformatics, bioconjugation, protein production and biology teams to seamlessly advance discovery programs
  • Regularly present research findings to the internal project teams and R&D Leadership
  • Comply with laboratory safety procedures and maintain compliant laboratory records
  • Routine maintenance of Mermade oligo synthesizer, HPLC, LC/MS and other lab equipment
  • Work with CROs to procure key intermediates and starting materials

Qualifications

  • Ph. D. in Organic chemistry/nucleic acid chemistry with 7+ years of postdoctoral/industry experience
  • Strong working experience in siRNA design, solid phase oligonucleotide synthesis and oligonucleotide SAR studies is required
  • Hands-on experience in novel phosphoramidite design and synthesis is required
  • Exceptional knowledge of basic oligonucleotide drug discovery and biology principles is required
  • Prior experience working with CDMOs on oligonucleotide production is a plus
  • Effective communication skills, both written and oral with an ability to organize and communicate complex data sets in a clear and concise manner
  • Demonstrated ability to work effectively in a collaborative team is critical
  • The successful candidate will have strong people skills, passion for science and the excitement for developing highly innovative technologies

Aro Biotherapeutics is an equal opportunity employer that is committed to diversity and inclusion in the workplace. We prohibit discrimination and harassment of any kind based on race, color, sex, religion, sexual orientation, gender identity/gender expression, national origin, disability, genetic information, pregnancy, or any other protected characteristic as outlined by federal, state, or local laws.

Aro Biotherapeutics offers a competitive benefits package including:

  • A variety of health insurance options at competitive rates
  • Flexible Spending Accounts
  • Paid Time off, including personal and vacation time
  • Company holidays
  • 401(k) with company match
  • Disability and Life Insurance
  • Commuter Benefits
  • Employee training and development opportunities
  • And more!

Aro Biotherapeutics is an equal opportunity employer; all qualified applicants will be considered for employment without regard for any characteristic protected by law. Aro Biotherapeutics provides a competitive benefits package.


About Aro Biotherapeutics

Join the team at Aro Biotherapeutics creating breakthrough biotherapeutics based on Centyrin oligonucleotide conjugates. Centyrins are small protein domains based on the fibronectin domains of human Tenascin C that combine the affinity and specificity properties of antibodies with the stability and tissue penetration properties of small molecules. We have engineered Centyrins with an array of specificities for normal and immune cell receptors. By linking Centyrin domains together genetically, we have created multi-specific binders that retain a small footprint to enable excellent tissue penetration. Engineered for high stability, multi-specific Centyrins are readily expressed and purified from E. coli or mammalian cells.

We are developing a platform for delivery of an array of intracellularly active payloads with a focus on oligonucleotides. Our team has built a strong set of in vitro and in vivo data validating the utility of Centyrins for receptor specific uptake in a variety of cell types. Centyrin conjugate mediated delivery provides the foundation for access to a set of intracellular targets that have long been considered undruggable.

Aro is building a wholly owned portfolio of Centyrin oligonucleotide conjugates for genetic and autoimmune diseases and developing a partnered portfolio of Centyrin conjugates for payload delivery in a variety of disease areas. Led by an experienced and exceptional team, Aro is backed by an exceptional syndicate that supports our commitment to advancing drug candidates with the potential to improve patient’s lives and to building an ideal environment for scientific and leadership growth.